NCT07400926 Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
| NCT ID | NCT07400926 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Glaukos Corporation |
| Condition | Open Angle Glaucoma (OAG) |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-17 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2025-12-17 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Open-angle glaucoma * 18 years of age or older Exclusion Criteria: * Subject who is breast-feeding or pregnant
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07400926 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Open Angle Glaucoma (OAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07400926 currently recruiting?
Yes, NCT07400926 is actively recruiting participants. Contact the research team at ClinicalResearch@glaukos.com for enrollment information.
Where is the NCT07400926 trial being conducted?
This trial is being conducted at Kenosha, United States.
Who is sponsoring the NCT07400926 clinical trial?
NCT07400926 is sponsored by Glaukos Corporation. The trial plans to enroll 30 participants.